This article is more than 5 years old. Information may no longer be current.

Allergan reports $1.53 billion in product net sales for third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan reported $1.53 billion in total product net sales for the third quarter, an increase of 12.9% over the third quarter 2012, according to a press release.

Total specialty pharmaceuticals net sales increased 12.8% compared with the third quarter of 2012, and total medical devices net sales increased 13.4%.

Quarterly diluted earnings per share attributable to stockholders totaled $1.10, up from $0.82 reported for the same period last year. Non-GAAP diluted earnings per share attributable to stockholders totaled $1.23, up from $1.04 a year ago.

For the full year, Allergan expects total product net sales to be between $6.1 billion and $6.2 billion, excluding the obesity intervention business.

The board of directors declared a third-quarter dividend of $0.05 per share, payable on Dec. 11 to stockholders of record on Nov. 20.